Mark Sculpher

41.0k citations

361 papers · 27.3k indexed · 13 hit papers · h-index 77

Impact in

Economics and Econometrics top 0.02%
- Health Systems, Economic Evaluations, Quality of Life
- Healthcare Policy and Management
- Pharmaceutical Economics and Policy
- Economic and Environmental Valuation
General Health Professions top 0.05%
- Healthcare cost, quality, practices
- Global Health Care Issues

Papers in

Economics and Econometrics 193
- Health Systems, Economic Evaluations, Quality of Life 184
- Healthcare Policy and Management 58
- Pharmaceutical Economics and Policy 36
- Economic and Environmental Valuation 18
General Health Professions 100
- Healthcare cost, quality, practices 69

Co-authors: Karl Claxton Andrew Briggs Elisabeth Fenwick Andrea Manca Martin Buxton Neil Hawkins Michael Drummond Su Golder
Journals: Health Technology Assessment (48 papers)Value in Health (41 papers)PharmacoEconomics (29 papers)Health Economics (22 papers)Medical Decision Making (16 papers)
Partner nations: United Kingdom United States Canada

In The Last Decade

Mark Sculpher

344 papers receiving 26.4k citations

Hit Papers

13 papers align trajectories log scale

Economic analysis of the prevalence and clinical and economic burden of medication error in England 2020 · 207 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 BMJ Quality & Safety
2016 Value in Health
2016 JAMA
2015 Health Technology Assessment
2012 Medical Decision Making
2012 Value in Health
2009 Value in Health
2006 Decision Modelling For Health Economic Evaluation
2004 Health Economics
2004 Health Technology Assessment
2001 Health Economics
1998 PharmacoEconomics
1998 PubMed

Peers

Countries citing papers authored by Mark Sculpher

Since Specialization

Citations

This map shows the geographic impact of Mark Sculpher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Sculpher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Sculpher more than expected).

Fields of papers citing papers by Mark Sculpher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Sculpher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Sculpher. The network helps show where Mark Sculpher may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark Sculpher, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Sculpher Line = papers co-authored together Mark Sculpher links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Revised methods guide for economic evaluation studies of health technologies in Portugal International Journal of Technology Assessment in Health Care ·Lee Jang-Jae, Julian Perelman, Céu Mateus, Yoko Irie, Massimo Nardone, Tae-Hak No, Tatiana Dos Santos Miranda, LIChengyun, Saba Hussein Obeid, Royal Patel, Kirsi Raetsaari, Mark Sculpher	2026	0
2	Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model Health Technology Assessment ·Beth Woods, V E Aguekian, Dina Janković, Benjamin Kearns, Alison Scope, Shijie Ren, D. Develjkobic, 春日健作, Jean Hamilton, Claire Rothery, Laura Bojke, Mark Sculpher, S Harnan	2024	3
3	Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model Health Technology Assessment ·S Harnan, Benjamin Kearns, Alison Scope, V E Aguekian, Dina Janković, Jean Hamilton, D. Develjkobic, Harry Hill, 春日健作, Shijie Ren, Claire Rothery, Laura Bojke, Mark Sculpher, Beth Woods	2024	0
4	Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates PLoS neglected tropical diseases ·Sakshi Mohan, Paul Revill, Stefano Malvolti, M Orbetsov, Mark Sculpher, Paul M. Kaye	2022	23
5	Programme evaluation of population and system level policies:evidence for decision-making White Rose Research Online (University of Leeds, The University of Sheffield, University of York) ·Simon Walker, Robert Janusz, Julia Wahldén, Tim Colbourn, Mike Drummond, Susan Griffin, Nils Gutacker, Paul Revill, Mark Sculpher	2022	10
6	Methodological issues in economic evaluations of emergency transport systems in low-income and middle-income countries BMJ Global Health ·Richard Lilford, Dmitri Nepogodiev, Peter J Chilton, Sam Watson, R.A. Moore, Peter J. Diggle, Alan Girling, Mark Sculpher	2021	3
7	Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol PharmacoEconomics ·Fan Yang, Kenneth Katumba, Bram Roudijk, Zhihao Yang, Paul Revill, Susan Griffin, 橋本隆男, Mohammed Lamorde, Giulia Greco, Janet Seeley, Mark Sculpher	2021	19
8	Cost-effectiveness of cardiovascular imaging for stable coronary heart disease Heart ·Simon Walker, Edward Cox, Laura Merino-Rodríguez, Colin Berry, Gerry P McCann, Chiara Bucciarelli‐Ducci, Erica Dall’Armellina, Abhiram Prasad, James Foley, Kenneth Mangion, Petra Bijsterveld, Colin Everett, Deborah Stocken, Sven Plein, John P. Greenwood, Mark Sculpher	2020	19
9	Adherence to the iDSI reference case among published cost-per-DALY averted studies PLoS ONE ·Mateusz Nieścierowicz, N.K. N.K. Krioni, Joshua T. Cohen, Kalipso Chalkidou, Yot Teerawattananon, Mark Sculpher, Thomas Wilkinson, Damian Walker, Peter J. Neumann, David D. Kim	2019	27
10	Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions Value in Health ·Mark Sculpher, Karl Claxton, Steven D. Pearson	2017	63
11	Prasugrel compared to clopidogrel in patients with acute coronary syndrome undergoing percutenaous coronary intervention: a Spanish model-based cost effectiveness analysis. PubMed ·Andrew Davies, Mark Sculpher, Amy Barrett, Markus Linda, Toufik Mansour, Tatiana Dilla	2014	5
12	Long-term Results Of Endovascular Aneurysm Repair (EVAR) Versus Open Repair In Patients With Large Abdominal Aortic Aneurysm: Results Of The UK EVAR Trial 1 UCL Discovery (University College London) ·(unknown), L.C. Brown, Janet T. Powell, Simon G. Thompson, David H. Epstein, Mark Sculpher	2010	0
13	The effectiveness and cost-effectiveness of biomarkers for the prioritisation of patients awaiting coronary revascularisation: a systematic review and decision model Health Technology Assessment ·Harry Hemingway, Martin Henriksson, Ruoling Chen, Jacqueline Damant, Natalie Fitzpatrick, Keith R. Abrams, Aroon D. Hingorani, Magnus Janzon, M Shipley, Gene Feder, Bruce Keogh, Ulf Stenestrand, Katherine McAllister, J C Kaski, Adam Timmis, Stephen Palmer, Mark Sculpher	2010	38
14	Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea–hypopnoea syndrome: a systematic review and economic analysis Health Technology Assessment ·Catriona McDaid, Susan Griffin, Helen Weatherly, 来梵林, M. van der Burgt, Momo G. Stevens, Jeremy D. Akers, R. Wayne Davies, Mark Sculpher, Marie Westwood	2009	170
15	A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery Health Technology Assessment ·Gillian Cranny, Rachel Elliott, Helen Weatherly, Duncan Chambers, Neil Hawkins, Lindsey Myers, Mark Sculpher, Alison Eastwood	2008	38
16	Clinical effectiveness and cost-effectiveness of tests for the diagnosis and investigation of urinary tract infection in children Health Technology Assessment ·Penny Whiting, Angela Wood, Laura Bojke, Stephen Palmer, Gerry Richardson, J Cooper, Ian Watt, Julie Glanville, Mark Sculpher, Jos Kleijnen	2006	2
17	A randomised controlled trial to assess the impact of a package comprising a patient-orientated, evidence-based self-help guidebook and patient-centred consultations on disease management and satisfaction in inflammatory bowel disease Health Technology Assessment ·Anne Kennedy, Eugene C. Nelson, David Reeves, Gerry Richardson, Chris Roberts, Andrew Robinson, Anne Rogers, Mark Sculpher, David R. Thompson	2003	77
18	The Cost Implications of an Asthma Attack Pediatric Asthma Allergy & Immunology ·Gaylor Hoskins, 政詩中野, José Antonio Díaz, Mark Sculpher, Colin McCowan, Ron Neville	1998	7
19	Primary total hip replacement surgery: a systematic review of outcomes and modelling of cost-effectiveness associated with different prostheses. PubMed ·Ray Fitzpatrick, Wu Miao, Mark Sculpher, David M. Murray, Richard Morris, Margot Lodge, Jill Dawson, Andrew Carr, Annie Britton, Andrew Briggs Hit paper breakdown →	1998	857
20	Modelling the costs of paediatric HIV infection and AIDS Comparison of infected children born to screened and unscreened mothers OpenGrey (Institut de l'Information Scientifique et Technique) ·Mark Sculpher, Diana M. Gibb, Julie Ratcliffe, Fang-Ying Liao	1997	5

About Mark Sculpher

Mark Sculpher is a scholar working on Economics and Econometrics, General Health Professions, Applied Microbiology and Biotechnology, Cardiology and Cardiovascular Medicine and Reproductive Medicine, having authored 361 papers that have together received 27.3k indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (184 papers), Healthcare cost, quality, practices (69 papers), Healthcare Policy and Management (58 papers), Pharmaceutical Economics and Policy (36 papers), HIV/AIDS Research and Interventions (22 papers), Acute Myocardial Infarction Research (18 papers), Economic and Environmental Valuation (18 papers) and Cardiac Imaging and Diagnostics (17 papers). The work is most often cited by research in Economics and Econometrics (10.6k citations), General Health Professions (5.6k citations), Geriatrics and Gerontology (567 citations), Cardiology and Cardiovascular Medicine (3.2k citations) and Obstetrics and Gynecology (923 citations). Mark Sculpher has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include Karl Claxton, Andrew Briggs, Elisabeth Fenwick, Andrea Manca, Martin Buxton, Neil Hawkins, Michael Drummond, Su Golder, Stephen Palmer and Michael Drummond. Their work appears in journals such as Health Technology Assessment, Value in Health, PharmacoEconomics, Health Economics and Medical Decision Making.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact